Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Surveillance Study for the Safety of Hexaxim®, a DTaP-IPV- HB-PRP~T Vaccine Administered to Infants From 2 Months of Age in Republic of Korea

NCT06793826 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.

NCT NCT06793826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06793826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Surveillance Study for the Safety of Hexaxim®, a DTaP-IPV- HB-PRP~T Vaccine Administered to Infants From 2 Months of Age in Republic of Korea
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Phase
Observational
Overall status
Completed
Start date
January 17, 2025
Completion date
January 15, 2026
Enrollment
713 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

haemophilus influenzae type b immunisation, hepatitis b